Menu
Search
|

Menu

Close
X

Tonix Pharmaceuticals Holding Corp TNXP.OQ (NASDAQ Stock Exchange Global Market)

3.41 USD
+0.03 (+0.89%)
As of Feb 23
chart
Previous Close 3.38
Open 3.36
Volume 1,750
3m Avg Volume 14,768
Today’s High 3.41
Today’s Low 3.36
52 Week High 9.38
52 Week Low 2.85
Shares Outstanding (mil) 7.51
Market Capitalization (mil) 36.27
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.694
FY16
-17.355
FY15
-28.635
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.07
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-77.69
14.43
Return on Equity (TTM)
vs sector
-77.82
16.13

EXECUTIVE LEADERSHIP

Seth Lederman
Chairman of the Board, President, Chief Executive Officer, Since 2011
Salary: $472,500.00
Bonus: --
Bradley Saenger
Chief Financial Officer, Treasurer, Since 2016
Salary: $301,361.00
Bonus: --
Jessica Morris
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Gregory Sullivan
Secretary,Chief Medical Officer, Since 2017
Salary: $335,000.00
Bonus: --
John Rhodes
Lead Independent Director, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

509 Madison Ave Rm 306
NEW YORK   NY   10022-5583

Phone: +1212.9809155

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).

SPONSORED STORIES